BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Upreti H, Kasmani J, Dane K, Braunstein EM, Streiff MB, Shanbhag S, Moliterno AR, Sperati CJ, Gottesman RF, Brodsky RA, Kickler TS, Chaturvedi S. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood 2019;134:1037-45. [PMID: 31431443 DOI: 10.1182/blood.2019001056] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Shao B, Nusrat S, George JN, Xia L. Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura? Am J Hematol 2022. [PMID: 35593427 DOI: 10.1002/ajh.26603] [Reference Citation Analysis]
2 Subhan M, Scully M. Advances in the management of TTP. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Bae SH, Kim SH, Bang SM. Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura. Blood Res 2022;57:37-43. [PMID: 35483924 DOI: 10.5045/br.2022.2022005] [Reference Citation Analysis]
4 Moosavi H, Ma Y, Miller MJ, Duncan A. Validation of PLASMIC score: an academic medical center case series (2012-present). Transfusion 2020;60:1536-43. [PMID: 32588918 DOI: 10.1111/trf.15916] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Graça NAG, Joly BS, Voorberg J, Vanhoorelbeke K, Béranger N, Veyradier A, Coppo P. TTP: From empiricism for an enigmatic disease to targeted molecular therapies. Br J Haematol 2022. [PMID: 35146746 DOI: 10.1111/bjh.18040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sukumar S, Gavriilaki E, Chaturvedi S. Updates on thrombotic thrombocytopenic purpura: Recent developments in pathogenesis, treatment and survivorship. Thrombosis Update 2021;5:100062. [DOI: 10.1016/j.tru.2021.100062] [Reference Citation Analysis]
7 Prevel R, Roubaud-Baudron C, Tellier E, Le Besnerais M, Kaplanski G, Veyradier A, Benhamou Y, Coppo P; Centre National de Référence des Microangiopathies Thrombotiques. [Endothelial dysfunction in thrombotic thrombocytopenic purpura: therapeutic perspectives]. Rev Med Interne 2021;42:202-9. [PMID: 33455838 DOI: 10.1016/j.revmed.2020.12.011] [Reference Citation Analysis]
8 Perez Botero J, Reese JA, George JN, McIntosh JJ. Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist. Am J Hematol 2021;96:1655-65. [PMID: 34424560 DOI: 10.1002/ajh.26328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
9 Albo Z, Mathew C, Catton R, Silver B, Moonis M. Thrombotic Thrombocytopenic Purpura (ADAMTS13 [a Disintegrin and Metalloproteinase With a Thrombospondin Type 1 Motif, Member 13] Deficiency) as Cause of Recurrent Multiterritory Ischemic Strokes. Stroke 2022;53:e237-40. [PMID: 35341321 DOI: 10.1161/STROKEAHA.121.034434] [Reference Citation Analysis]
10 Chaturvedi S, Cuker A. Different strokes for older folks (with TTP). Blood 2019;134:2125-6. [DOI: 10.1182/blood.2019003430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, Kremer Hovinga JA, Lämmle B, Matsumoto M, Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas MR, Tomiyama Y, Veyradier A, Westwood JP, Scully M. Redefining outcomes in immune TTP: an international working group consensus report. Blood 2021;137:1855-61. [PMID: 33529333 DOI: 10.1182/blood.2020009150] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
12 Gómez-Seguí I, Pascual Izquierdo C, de la Rubia Comos J. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;14:707-19. [PMID: 34275393 DOI: 10.1080/17474086.2021.1956898] [Reference Citation Analysis]
13 Zheng XL. The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost 2021;19:1864-71. [PMID: 34060225 DOI: 10.1111/jth.15406] [Reference Citation Analysis]
14 Delrue M, Baylatry MT, Joly AC, Corre E, Marjanovic Z, El-Khoury-Hanna N, Féger F, Suner L, Veyradier A, Stépanian A, Coppo P. Efficacy of subcutaneous preemptive rituximab in immune-mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases. Am J Hematol 2021;96:E26-9. [PMID: 33068040 DOI: 10.1002/ajh.26022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Kremer Hovinga JA, Braschler TR, Buchkremer F, Farese S, Hengartner H, Lovey PY, Largiadèr CR, Mansouri Taleghani B, Tarasco E. Insights from the Hereditary Thrombotic Thrombocytopenic Purpura Registry: Discussion of Key Findings Based on Individual Cases from Switzerland. Hamostaseologie 2020;40:S5-S14. [PMID: 33187004 DOI: 10.1055/a-1282-2264] [Reference Citation Analysis]
16 Matthews A, Yui J, Chiang EY, Pishko AM, Cuker A, Cucchiara BL, George D, Sayani F, Mullen MT. Cerebral Infarction due to Severe ADAMTS-13 Deficiency with Normal Hematological Parameters: A Potentially Cause of Cryptogenic Stroke. J Stroke Cerebrovasc Dis 2022;31:106431. [PMID: 35305536 DOI: 10.1016/j.jstrokecerebrovasdis.2022.106431] [Reference Citation Analysis]
17 Beltrami-Moreira M, DeSancho MT. Delayed diagnosis of congenital thrombotic thrombocytopenic purpura in a patient with recurrent strokes. J Thromb Thrombolysis 2022. [PMID: 35022991 DOI: 10.1007/s11239-021-02629-7] [Reference Citation Analysis]
18 Pavenski K, Huang SS, Patriquin CJ. Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;:1-14. [PMID: 34747320 DOI: 10.1080/17474086.2021.2003703] [Reference Citation Analysis]
19 Brodsky MA, Sukumar S, Selvakumar S, Yanek L, Hussain S, Mazepa MA, Braunstein EM, Moliterno AR, Kickler TS, Brodsky RA, Cataland SR, Chaturvedi S. Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura. Am J Hematol 2021;96:1587-94. [PMID: 34460124 DOI: 10.1002/ajh.26341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Santamaria S, de Groot R. ADAMTS proteases in cardiovascular physiology and disease. Open Biol 2020;10:200333. [PMID: 33352066 DOI: 10.1098/rsob.200333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
21 Marcellini Antonio S, Valencia Castillo S, Díaz Valdés J, Torres Tienza A, Zato Hernández E, García Mateo A, Llorente Melgar MD, Olivier Cornacchia MC, Queizán Hernández JA. Clinical management and follow-up of relapsed immune thrombotic thrombocytopenic purpura during pregnancy: A case report. Thromb Res 2020;194:91-4. [PMID: 32788126 DOI: 10.1016/j.thromres.2020.06.020] [Reference Citation Analysis]
22 Westwood JP, Scully M. Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase. Therapeutic Advances in Hematology 2022;13:204062072211122. [DOI: 10.1177/20406207221112217] [Reference Citation Analysis]
23 Borogovac A, George JN. Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: similarities to sickle cell anemia. Blood Adv 2019;3:3973-6. [PMID: 31805189 DOI: 10.1182/bloodadvances.2019000959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
24 Huang SS, Pavenski K, Lee TY, Jurkiewicz MT, Bharatha A, Thiessen JD, St Lawrence K, Théberge J, Mandzia J, Barth D, Licht C, Patriquin CJ. Blood-brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study. Blood Adv 2021;5:4211-8. [PMID: 34521110 DOI: 10.1182/bloodadvances.2021005317] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 George JN. Thrombotic Thrombocytopenic Purpura: From 1972 to 2022 and Beyond. Semin Thromb Hemost 2022. [PMID: 35793688 DOI: 10.1055/s-0042-1749589] [Reference Citation Analysis]
26 Li A, Kremer Hovinga JA. Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2020;2020:82-4. [PMID: 33275690 DOI: 10.1182/hematology.2020000164] [Reference Citation Analysis]
27 Ferro JM, Infante J. Cerebrovascular manifestations in hematological diseases: an update.J Neurol. 2021;268:3480-3492. [PMID: 33586004 DOI: 10.1007/s00415-021-10441-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Shaw RJ, Dutt T. Mind and matter: The neurological complications of thrombotic thrombocytopenic purpura. Br J Haematol. [DOI: 10.1111/bjh.18127] [Reference Citation Analysis]
29 Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, Novembrino C, Boscolo Anzoletti M, De Zan V, Pagliari MT, Gualtierotti R, Aliberti S, Panigada M, Grasselli G, Blasi F, Peyvandi F. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost 2021;19:513-21. [PMID: 33230904 DOI: 10.1111/jth.15191] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
30 Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med 2021;10:536. [PMID: 33540569 DOI: 10.3390/jcm10030536] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
31 Galstyan GM, Maschan AA, Klebanova EE, Kalinina II. Treatment of thrombotic thrombocytopenic purpura. Terapevticheskii arkhiv 2021;93:736-45. [DOI: 10.26442/00403660.2021.06.200894] [Reference Citation Analysis]